首页> 外文期刊>MedChemComm >New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators
【24h】

New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators

机译:评估6-硫嘌呤毒性并通过小分子增强剂将治疗应用扩展其治疗癌症的新方法

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

6-Thiopurine (6TP) is a potent cytotoxic agent that is a clinically prescribed anti-metabolite employed in the treatment of numerous blood cancers since 1952. However, its reported severe toxicities limit its general usage in the clinic. We previously have undertaken investigations into identifying the mode of toxicity for 6TP, and have found that the oxidative metabolites of 6TP, specifically 6-thiouric acid (6TU), is responsible for the in vitro inhibition of UDP-glucose dehydrogenase (UDPGDH) in a UV-vis method. In this method, inhibition was quantified through the quantification of NADH production, however, purines absorb at the same wavelength and thereby can interfere with the NADH detection. Herein, we report a HPLC method that allows for direct quantification of UDP-glucuronic acid, product from UDPGDH, for the assessment of inhibition towards UDPGDH with no interference from purines. In this method it was revealed that 6TP possesses a greater inhibitory properties than previously observed; 111 vs. 288 μM. Building upon the data collected from a previously performed rat hepatocyte study, which correlated our in vitro to in vivo inhibition theories about UDPGDH, we have developed a bio-mimic in vitro assay to aid in the inhibitory assessment of 6TP and analogs. In our efforts to expand the use of 6TP, and analogs constructed, our laboratory has undertaken a screening campaign to identify small molecule potentiators that work in synergy with 6TP in other types of cancers. Three chalcone-based compounds have been discovered through our total synthesis campaign of uvaretin, and it has been found that 11c has strong synergism with 6TP in the pancreatic cancer cell line MIA PaCa-2. Through the work presented herein, we reveal new methods to assess toxicity of 6TP and future analogs and new small molecules that work in synergy to expand the therapeutic applications of this neglected cytotoxic agent.
机译:6-硫嘌呤(6TP)是一种有效的细胞毒性剂,其自1952年以来,是在治疗无数血癌的临床规定的抗代谢物。然而,其报告的严重毒性限制了临床的一般用途。我们之前已经进行了调查,鉴定了6TP的毒性模式,并发现6TP,特别是6-硫酸(6Tu)的氧化代谢物负责UDP-葡萄糖脱氢酶(UDPGDH)中的体外抑制UV-VIS方法。在该方法中,通过量化NADH产生量化抑制,然而,嘌呤在相同的波长处吸收,从而可以干扰NADH检测。在此,我们报告了一种HPLC方法,其允许直接定量UDP-葡糖醛酸,来自UDPGDH的产品,用于评估抑制UDPGDH,没有干扰嘌呤的干扰。在该方法中,揭示了6TP具有比先前观察到更大的抑制性质; 111vs.288μm。根据先前进行的大鼠肝细胞研究收集的数据,其在体外与体外抑制有关UDPGDH的抑制作用,我们开发了一种生物模拟体外测定,以帮助抑制6TP和类似物的抑制评估。在我们努力扩大使用6TP的使用和建造的类似物,我们的实验室已经开展了筛选活动,以确定在其他类型的癌症中有6TP的协同作用工作的小分子增强剂。通过我们的Uvaretin总综合运动发现了三种基于Chalcone的化合物,发现11C具有强烈的协同作用,在胰腺癌细胞系MIA PACA-2中具有强烈的协同作用。通过本文提出的工作,我们揭示了评估6TP和未来类似物和新的小分子的毒性的新方法,这些方法和新的小分子在协同作用中展开这种被忽略的细胞毒性剂的治疗应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号